- Home
- KOD vs SLS Comparison
KOD vs SLS Comparison
Compare KOD & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- SLS
- Stock Information
- Founded
- KOD 2009
- SLS 2012
- Country
- KOD United States
- SLS United States
- Employees
- KOD N/A
- SLS N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- KOD Health Care
- SLS Health Care
- Exchange
- KOD Nasdaq
- SLS Nasdaq
- Market Cap
- KOD 198.4M
- SLS 169.6M
- IPO Year
- KOD 2018
- SLS N/A
- Fundamental
- Price
- KOD $8.84
- SLS $1.80
- Analyst Decision
- KOD Hold
- SLS Strong Buy
- Analyst Count
- KOD 3
- SLS 1
- Target Price
- KOD $9.00
- SLS $7.00
- AVG Volume (30 Days)
- KOD 549.8K
- SLS 3.7M
- Earning Date
- KOD 08-13-2025
- SLS 08-12-2025
- Dividend Yield
- KOD N/A
- SLS N/A
- EPS Growth
- KOD N/A
- SLS N/A
- EPS
- KOD N/A
- SLS N/A
- Revenue
- KOD N/A
- SLS N/A
- Revenue This Year
- KOD N/A
- SLS N/A
- Revenue Next Year
- KOD N/A
- SLS N/A
- P/E Ratio
- KOD N/A
- SLS N/A
- Revenue Growth
- KOD N/A
- SLS N/A
- 52 Week Low
- KOD $1.92
- SLS $0.77
- 52 Week High
- KOD $11.60
- SLS $2.27
- Technical
- Relative Strength Index (RSI)
- KOD 84.50
- SLS 46.63
- Support Level
- KOD $5.00
- SLS $1.75
- Resistance Level
- KOD $5.73
- SLS $1.96
- Average True Range (ATR)
- KOD 0.70
- SLS 0.13
- MACD
- KOD 0.42
- SLS -0.03
- Stochastic Oscillator
- KOD 99.61
- SLS 11.90
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.